DPP-8 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Dipeptidyl Peptidase 8 (DPP-8/Q6V1X1), expressed in HEK293 cells. Used in prolyl dipeptidase activity assays, DPP8/9 inhibitor profiling, NLRP1-CARD8 inflammasome research, and antibody validation.
Expression system
HEK293
Cat. #
REC-DPP8

In stock

SKU
REC-DPP8
$498.00

Target Overview

DPP-8 (UniProt Q6V1X1; gene DPP8) is a cytoplasmic serine prolyl dipeptidase classified under EC 3.4.14.5. The full-length human protein spans 898 amino acids and belongs to the same structural family as DPP4 and DPP9, sharing the conserved S9B prolyl oligopeptidase fold. This recombinant is produced in HEK293 mammalian cells, which support the post-translational folding and glycosylation environment appropriate for a cytoplasmic enzyme of this complexity. Enzymatically, DPP-8 cleaves N-terminal dipeptides from peptide substrates carrying a proline or alanine at position 2, the canonical X-Pro/Ala specificity shared across the DPP4 subfamily. This activity can be measured directly using synthetic fluorogenic substrates (e.g., Gly-Pro-AMC or Ala-Pro-AMC) in continuous kinetic assays, making this recombinant well suited to enzyme kinetic characterisation, kcat/Km determination, and inhibitor IC50 profiling under defined conditions. Beyond its catalytic role, DPP-8 functions as a key suppressor of NLRP1 and CARD8 inflammasome activation in resting monocytes and macrophages. It sequesters the processed C-terminal fragments of NLRP1 and CARD8 in a ternary repressive complex, preventing their oligomerisation. This non-catalytic scaffolding role makes DPP-8 a mechanistically distinct research tool from DPP4 and is a primary reason the protein is studied in innate immune signalling contexts. Researchers requiring a positive control antigen for Western blot or immunohistochemistry can pair this recombinant with the Triple Point Biologics matched antibody (RP-DPP8), which has been validated in both applications. Use of the same expression system for antigen and antibody validation reduces background attributable to host-cell contaminants.

Background

DPP-8 is a cytoplasmic dipeptidyl peptidase first characterised in the early 2000s as a member of the DPP4 enzyme family. Unlike DPP4, which is a type II transmembrane ectopeptidase, DPP-8 is confined to the cytoplasm and lacks a signal peptide or membrane anchor. Its prolyl dipeptidase activity (EC 3.4.14.5) was established through biochemical studies demonstrating cleavage of X-Pro and X-Ala dipeptides from synthetic fluorogenic substrates, and the enzyme has been characterised kinetically alongside its close paralogue DPP9. A defining area of DPP-8 research is its role in innate immune regulation. DPP-8 forms a ternary repressive complex with the cleaved C-terminal fragments of NLRP1 and CARD8 — the biologically active portions of two cytoplasmic inflammasome sensors — thereby preventing their oligomerisation into active inflammasomes and the downstream caspase-1-dependent pyroptosis that would follow. Critically, the dipeptidyl peptidase catalytic activity of DPP-8 is required for this suppressive function, yet NLRP1 and CARD8 themselves are not DPP-8 substrates, implying one or more upstream substrates remain to be identified. This mechanistic gap makes DPP-8 an active subject of substrate-identification and chemical biology studies. The DPP8/NLRP1/caspase-1/GSDMD axis has been investigated in neuroinflammatory contexts as well. Cui et al. (2026, J Neuroinflammation, PMID 41689046) examined how MST1 regulates this axis to promote microglial pyroptosis in a model relevant to Alzheimer's disease research, illustrating that DPP-8 signalling extends beyond peripheral monocytes into CNS-resident immune cells. Such studies rely on well-characterised recombinant DPP-8 to benchmark enzymatic activity and validate pathway perturbations. DPP-8 is also studied alongside DPP9 in chemical probe development. Small-molecule inhibitors with dual DPP8/9 activity (e.g., Val-boroPro/talabostat) are frequently used to trigger NLRP1/CARD8 inflammasome activation experimentally; selectivity profiling of next-generation inhibitors against recombinant DPP-8 versus DPP-9 requires active recombinant enzyme for in vitro IC50 determination (Sewald et al., 2025, Chembiochem, PMID 40939170; Filippi et al., 2025, J Med Chem, PMID 41160575). Because DPP8 and DPP9 share high structural homology, recombinant proteins from a defined expression system are essential for clean selectivity discrimination in such assays.

Applications

  • Continuous fluorogenic dipeptidase activity assay using Gly-Pro-AMC or Ala-Pro-AMC substrates
  • Inhibitor IC50 and selectivity profiling against DPP8 versus DPP9 in biochemical counterscreens
  • Enzyme kinetic characterisation (kcat, Km, Ki determination) under defined buffer conditions
  • NLRP1/CARD8 ternary complex reconstitution and binding studies (pull-down, SPR, ITC)
  • Antibody validation positive control for Western blot using matched RP-DPP8 antibody
  • Substrate identification by mass spectrometry-based cleavage profiling
  • Photocaged or covalent inhibitor target-engagement assays in cell-free format

References

  1. Cui D et al. MST1 promotes microglial pyroptosis and neuroinflammation in alzheimer's disease by regulating the novel DPP8/NLRP1/Caspase-1/GSDMD-N axis. J Neuroinflammation. 2026. doi:10.1186/s12974-026-03732-3. PMID: 41689046.
  2. Wirtgen VE et al. Proximity labeling reveals non-catalytic interactions between DPP9 and ubiquitin signaling complexes. Cell Mol Life Sci. 2026. doi:10.1007/s00018-025-06021-z. PMID: 41636814.
  3. Filippi N et al. Selective and Orally Bioavailable Dipeptidyl Peptidase 9 Inhibitors with Potent Pyroptosis Induction Properties. J Med Chem. 2025. doi:10.1021/acs.jmedchem.5c02049. PMID: 41160575.
  4. Sewald L et al. A Photocaged N-Phosphonopiperidinone as a Selective Photo-Cleavable DPP8/9 Inhibitor. Chembiochem. 2025. doi:10.1002/cbic.202500558. PMID: 40939170.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Subcellular localization not yet annotated

Frequently Asked Questions

What is the expected molecular weight of recombinant DPP-8 on SDS-PAGE and Western blot?

Full-length human DPP-8 (898 aa, UniProt Q6V1X1) has a predicted molecular weight of ~100 kDa from sequence alone. Because this recombinant is produced in HEK293 cells, N-linked glycosylation is expected to shift the apparent band to approximately 100–115 kDa on reducing SDS-PAGE. Purity is >90% by SDS-PAGE, so the dominant band at that position should be unambiguous. When running a Western blot positive control alongside RP-DPP8 antibody, load 20–50 ng per lane and expect a clean band in that 100–115 kDa window.

Does recombinant DPP-8 require any autocatalytic processing or is it active as a full-length protein?

Unlike some cysteine proteases that require zymogen activation, DPP-8 is active as the full-length 898-amino acid monomer — no propeptide cleavage is necessary. The catalytic triad (Ser, Asp, His) is constitutively accessible in the folded prolyl oligopeptidase (S9B) architecture. HEK293 expression ensures the cytoplasmic folding context required for this architecture. The recombinant is supplied in active solution form and should be functional immediately upon thaw, without any pre-activation step.

What substrates work best for measuring DPP-8 dipeptidyl peptidase activity in a fluorescence assay?

The two most widely validated fluorogenic substrates for DPP-8 are Gly-Pro-AMC and Ala-Pro-AMC, both cleaved at the Pro-AMC bond to release 7-amino-4-methylcoumarin (AMC), monitored at Ex/Em 360/460 nm. Gly-Pro-AMC is the conventional choice and allows direct comparison with published Km values for DPP4 and DPP9. Use substrate concentrations spanning 50–500 µM to bracket the Km for Km/kcat determination. H-Ala-Pro-pNA (chromogenic) is an alternative if fluorescence interference is a concern in your compound library.

What buffer conditions should I use to measure DPP-8 activity in a kinetic assay?

DPP-8 is active across a broad pH range, with optimal activity typically reported between pH 7.0 and 8.0. A practical starting buffer is 50 mM HEPES pH 7.5, 150 mM NaCl, 0.01% Tween-20, 1 mg/mL BSA at 37 °C. The 10% glycerol in the supplied storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) is diluted to ≤1% final in the assay to avoid viscosity effects. Avoid EDTA — DPP-8 activity is not metal-dependent, but chelators can interfere with assay stability at high concentrations.

How much recombinant DPP-8 should I use per well for an IC50 inhibitor profiling assay?

For a 96-well fluorescence kinetic assay with Gly-Pro-AMC (200 µM), a starting point of 5–20 nM recombinant DPP-8 per well (in 100 µL total volume) typically gives a robust signal-to-background ratio of ≥5 with a linear rate for 30–60 minutes at 37 °C. Titrate enzyme concentration in a preliminary linearity-of-signal experiment before committing compound. Pre-incubate enzyme with inhibitor for 30 minutes at room temperature before substrate addition to allow equilibrium binding, particularly important for slow-binding inhibitors.

Can I use DPP-8 (Recombinant) as a positive control for Western blot with the RP-DPP8 antibody?

Yes — this is a validated pairing. REC-DPP8 and RP-DPP8 (rabbit polyclonal, /anti-dpp-8-rabbit-polyclonal-antibody) are developed in the same laboratory, and compatibility for Western blot positive control use is confirmed. Load 20–50 ng of REC-DPP8 in a dedicated lane alongside your cell lysate. Under reducing conditions, the primary band should appear at approximately 100–115 kDa. This is particularly useful when working with cell lines where endogenous DPP-8 expression is low or variable, giving you a definitive size reference and antibody sensitivity benchmark.

How much recombinant DPP-8 protein should I load for a Western blot positive control lane?

20–50 ng per lane is a reliable starting range when using RP-DPP8 at a 1:500–1:2000 primary antibody dilution on standard PVDF or nitrocellulose membranes. If your lysate lanes are loaded at 20–30 µg total protein, 20 ng of REC-DPP8 is generally sufficient to produce a visible, non-saturating band without overwhelming adjacent lanes. Titrate down to 5 ng if you are optimizing signal linearity for quantitative Western applications. The >90% purity by SDS-PAGE ensures the signal reflects DPP-8 specifically, not a mixed-protein background.

How should I store and handle DPP-8 (Recombinant) to preserve enzymatic activity over time?

REC-DPP8 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and should be stored at -20 °C in single-use aliquots immediately upon receipt. Repeated freeze-thaw cycles progressively reduce specific activity — even two additional cycles can measurably impair kinetic performance for an enzyme of this complexity. For experiments running over several days, keep a working aliquot at 4 °C for up to 48 hours. Avoid diluting to very low concentrations (<1 nM) without carrier protein (0.1–1 mg/mL BSA), as surface adsorption losses become significant at those ranges.

Validation imagery coming soon

Western blot validation figures for REC-DPP8 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →